Literature DB >> 30401946

Revisiting the role of the pathological grading in pediatric adrenal cortical tumors: results from a national cohort study with pathological review.

Cécile Picard1, Daniel Orbach2, Matthieu Carton3, Laurence Brugieres4, Karine Renaudin5, Sébastien Aubert6, Dominique Berrebi7, Louise Galmiche8, Fanny Dujardin9, Pierre Leblond10, Cécile Thomas-Teinturier11,12, Frédérique Dijoud13.   

Abstract

The prognosis of malignant pediatric adrenocortical tumors is closely related to disease stage, which is used to guide perioperative treatment recommendations. However, current scoring systems are inadequate to distinguish between benign and malignant adrenocortical tumors. Robust microscopic prognostic features that could help determine perioperative therapy are also lacking. The aim of this national study was to review the prognostic value of the Wieneke scoring criteria and Ki67 labeling index in unselected pediatric adrenocortical tumors. Using strict definitions previously defined by expert pathologists, a Wieneke score was re-attributed to each tumor after an independent and centralized review. In addition, Ki67 proliferation index was performed and reviewed for each case. A total of 95 cases were selected; all were treated between 2000 and 2018 and had histopathologic material and sufficient outcome-related information available. Localized disease was found in 88% of patients. Among those with advanced disease, 6% had tumor extension into adjacent organs and 5% had metastases at diagnosis. Median follow-up was 5 years and 3 months. The 5-year PFS was 82%, 95% CI [73%-91%]. Tumor stage significantly correlated with PFS (p < 0.0001). Tumor weight up to 200 g, extra-adrenal extension and initial non-complete surgical resection were statistically associated with worse outcomes. No recurrences nor metastases occurred when the Ki67 index was < 15%. Up to two of the following five factors including tumor necrosis, adrenal capsular invasion, venous invasion, mitotic count > 15/20 high-power fields, and Ki67 index > 15%, significantly correlated with worse outcomes. We propose a pathological scoring system incorporating the Ki67 index as part of a two-step approach after disease staging to guide adjuvant treatment in pediatric adrenocortical tumors, especially after incomplete resection. These results should be validated in an independent cohort.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30401946     DOI: 10.1038/s41379-018-0174-8

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  12 in total

1.  Clinical Impact of Pathological Features Including the Ki-67 Labeling Index on Diagnosis and Prognosis of Adult and Pediatric Adrenocortical Tumors.

Authors:  Sebastiao N Martins-Filho; Madson Q Almeida; Ibere Soares; Alda Wakamatsu; Venancio Avancini F Alves; Maria Candida Barisson V Fragoso; Maria Claudia N Zerbini
Journal:  Endocr Pathol       Date:  2021-01-14       Impact factor: 3.943

2.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17

3.  Adrenocortical Tumors and Pheochromocytoma/Paraganglioma Initially Mistaken as Neuroblastoma-Experiences From the GPOH-MET Registry.

Authors:  Michaela Kuhlen; Christina Pamporaki; Marina Kunstreich; Stefan A Wudy; Michaela F Hartmann; Mirko Peitzsch; Christian Vokuhl; Guido Seitz; Michael C Kreissl; Thorsten Simon; Barbara Hero; Michael C Frühwald; Peter Vorwerk; Antje Redlich
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

Review 4.  Adrenal ganglioneuroma: Prognostic factors (Review).

Authors:  Florica Sandru; Mihai Cristian Dumitrascu; Aida Petca; Mara Carsote; Razvan-Cosmin Petca; Ana Maria Oproiu; Adina Ghemigian
Journal:  Exp Ther Med       Date:  2021-09-22       Impact factor: 2.751

Review 5.  Radiotherapy for pediatric adrenocortical carcinoma - Review of the literature.

Authors:  Verena Wiegering; Maria Riedmeier; Lester D R Thompson; Calogero Virgone; Antje Redlich; Michaela Kuhlen; Melis Gultekin; Bilgehan Yalcin; Boris Decarolis; Christoph Härtel; Paul-Gerhardt Schlegel; Martin Fassnacht; Beate Timmermann
Journal:  Clin Transl Radiat Oncol       Date:  2022-05-14

Review 6.  Multimodal Imaging Mass Spectrometry: Next Generation Molecular Mapping in Biology and Medicine.

Authors:  Elizabeth K Neumann; Katerina V Djambazova; Richard M Caprioli; Jeffrey M Spraggins
Journal:  J Am Soc Mass Spectrom       Date:  2020-09-04       Impact factor: 3.262

Review 7.  Adrenocortical Carcinoma: Updates of Clinical and Pathological Features after Renewed World Health Organisation Classification and Pathology Staging.

Authors:  Alfred King-Yin Lam
Journal:  Biomedicines       Date:  2021-02-10

8.  Recurrent malignant peripheral nerve sheath tumor presenting as an asymptomatic intravenous thrombus extending to the heart: a case report.

Authors:  Toru Hirozane; Robert Nakayama; Sayaka Yamaguchi; Tomoaki Mori; Naofumi Asano; Keisuke Asakura; Kazutaka Kikuta; Miho Kawaida; Aya Sasaki; Hajime Okita; Seishi Nakatsuka; Tsutomu Ito
Journal:  World J Surg Oncol       Date:  2022-01-07       Impact factor: 2.754

Review 9.  Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.

Authors:  Ozgur Mete; Lori A Erickson; C Christofer Juhlin; Ronald R de Krijger; Hironobu Sasano; Marco Volante; Mauro G Papotti
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 4.056

10.  Clinical, Genetic, and Prognostic Features of Adrenocortical Tumors in Children: A 10-Year Single-Center Experience.

Authors:  Evelina Miele; Angela Di Giannatale; Alessandro Crocoli; Raffaele Cozza; Annalisa Serra; Aurora Castellano; Antonella Cacchione; Maria Giuseppina Cefalo; Rita Alaggio; Maria Debora De Pasquale
Journal:  Front Oncol       Date:  2020-10-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.